title: Low-dose docetaxel/cisplatin - leucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma.
abstract: BACKGROUND
  Phase II and III trials of docetaxel, cisplatin and fluorouracil (DCF) have shown superior efficacy versus cisplatin and fluorouracil alone but with high rates of hematologic toxicity in metastatic gastric cancer cases. To reduce toxicity while maintaining the efficacy of DCF, we investigated low dose docetaxel (D), cispatin (C) - leucovorin and fluorouracil (De Gramont regimen).
  
  
  METHODS
  Chemotherapy-naive patients with metastatic gastric cancer (MGC) received D 60 mg/m2 on day 1 and cisplatin 30 mg/m2 on day 1-2 and the De Gramont regimen (Folinic acid 400 mg/m2 on day 1 and 5-FU 2400 mg/m2/46 h continuous infusion) every 3 weeks. The primary endpoint was response rate.
  
  
  RESULTS
  One hundred twenty patients with a median age of 52.5 years (range, 32-78) received a median of 6 cycles (range, 2-12 cycles). Of the 120 evaluable patients, 4 showed complete remission and 36 achieved a partial response. The overall response rate was 56.6%. Twenty eight patients (23.3%) showed stable disease and 52 (43.3%) progression. The median time to progression was 7 months (95%CI 6-7.9). The median overall survival was 15 months (95%CI 13.7-16.2). The most frequent hematological toxicity was leucopenia, which occurred at grade 3/4 intensity in 24 patients (20%).
  
  
  CONCLUSIONS
  Low-dose DC- De Gramont regimen is active in MGC with a tolerable toxicity profile.
authors.affiliation: Oncology of Department of Goztepe Medical Park Hospital, Medical School of Bahcesehir University, Istanbul, Turkey. suleymanalici@yahoo.com
authors.forename: Suleyman
authors.initials: S
authors.lastname: Alici
authors.forename: Suleyman
authors.initials: S
authors.lastname: Buyukberber
authors.forename: Necati
authors.initials: N
authors.lastname: Alkis
authors.forename: Mustafa
authors.initials: M
authors.lastname: Benekli
authors.forename: Metin
authors.initials: M
authors.lastname: Ozkan
authors.forename: Ahmet
authors.initials: A
authors.lastname: Bilici
authors.forename: Umut
authors.initials: U
authors.lastname: Demirci
authors.forename: Halit
authors.initials: H
authors.lastname: Karaca
authors.forename: Erkan
authors.initials: E
authors.lastname: Arpaci
authors.forename: Mahmut
authors.initials: M
authors.lastname: Gumus
authors.forename: Mustafa
authors.initials: M
authors.lastname: Altunbas
authors.forename: Faysal
authors.initials: F
authors.lastname: Dane
authors.forename: H Mehmet
authors.initials: HM
authors.lastname: Turk
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D018450:Disease Progression; D018572:Disease-Free Survival; D000077143:Docetaxel; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil